CellabMED

3 clinical trials · Sponsor

Record	Firm	Date
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients (NCT04368507)	CellabMED	2019-08-09

Every clearance here is in the API, with alerts when new ones post.